COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.

Hence, researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025, mostly in the second half of the year ... with no events meeting protocol-defined dose-limiting toxicity criteria.

Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025, mostly in the second half of the year ... well-tolerated to date with no events meeting protocol-defined dose-limiting toxicity ...

There's one big difference though - Pfizer is seeking a green light for second booster dose of Comirnaty for people aged 60 and over and those in high-risk groups, while Moderna is going for a ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Moderna has reported preliminary clinical ... that it is too early to consider widespread use of a second COVID-19 vaccine booster dose in the EU.